Form 4: ANI Pharmaceuticals Insider Sells Shares

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, Inc., sold 500 shares of common stock on May 13, 2026, pursuant to a pre-established 10b5-1 trading plan.

Summary

• Meredith Cook, the Senior Vice President, General Counsel & Secretary of ANI Pharmaceuticals, Inc., executed a sale of 500 shares of common stock.
• The transaction occurred on May 13, 2026, and the sale price was $78.16 per share.
• This sale was conducted under a Rule 10b5-1 trading plan, which was adopted by the reporting person on September 15, 2025.
• Following the transaction, Meredith Cook beneficially owns 78,390 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider sales can be a negative signal, the transaction was conducted under a pre-arranged 10b5-1 plan, mitigating concerns about opportunistic trading.

Negatives

• Insider selling can sometimes be interpreted as a negative signal by the market, although in this case it was executed under a pre-planned trading strategy.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely monitored by investors. The execution of a Rule 10b5-1 plan indicates a pre-determined strategy for stock sales, often used by executives to diversify holdings or meet financial obligations without appearing to trade on material non-public information. This is a common practice in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: May view insider sales with caution, though the 10b5-1 plan provides context that may reduce negative sentiment.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Meredith Cook